Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

MYSTIC Trial Analysis IDs Mutations Prognostic of mNSCLC Outcomes

Publish date:: September 24, 2019

Key clinical point: Mutations in certain tumor suppressor genes are prognostic for OS in mNSCLC.

Major finding: ORRs for durvalumab + tremelimumab treated patients with ARID1am vs. ARID1awt were 51.3% vs. 19.4%, respectively.

Study details: An analysis of 943 samples from the open-label phase 3 MYSTIC trial.

Disclosures: The MYSTIC trial was sponsored by AstraZeneca. Dr. Rizvi disclosed royalties related to intellectual property/patents filed by MSKCC and Personal Genome Diagnostics.

Citation:

Rizvi N et al. WCLC 2019: Abstract OA04.07.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lung Cancer

Two different radiation boost strategies reduce local failures in NSCLC,

Rechallenge ‘reasonable’ for some with small-cell lung cancer,

Black patients with ES-SCLC get less chemo but have better survival,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,